Skip to Content

What is the difference between Basaglar and Lantus?

Answers (1)

Official Answer by Drugs.com 9 Mar 2016

Basaglar is insulin glargine injection, approved in Dec 2015 and manufactured by Eli Lilly. Basaglar is a "follow-on" product to Lantus (insulin glargine injection), made by sanofi-aventis.

They are both long-acting human insulin analogues used for blood glucose (sugar) control in adult and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.

Basaglar is administered subcutaneously once daily by the KwikPen at the same time every day.

The FDA does not consider Basaglar a biosimilar to Lantus. FDA did not approve Basaglar as a biosimilar to Lantus because Lantus was not approved under the Public Health Service Act, so there is no “reference product” for a proposed biosimilar product.

Votes: +0
Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

How do you calculate the dosage for Carnexiv?

Posted 5 days ago 1 answerFAQ by Drugs.com

What is the difference between Amjevita and Humira?

Posted 5 days ago 1 answerFAQ by Drugs.com

What are the clinical benefits of Exondys 51?

Posted 5 days ago 1 answerFAQ by Drugs.com

How is Cuvitru administered?

Posted 5 days ago 1 answerFAQ by Drugs.com

How is Troxyca ER formulated to be abuse deterrent?

Posted 5 days ago 1 answerFAQ by Drugs.com